Literature DB >> 22863838

Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities.

Kenji Ito1, Hitoshi Nakashima, Maho Watanabe, Atsunori Ishimura, Yoshito Miyahara, Yasuhiro Abe, Tetsuhiko Yasuno, Masakazu Ifuku, Yoshie Sasatomi, Takao Saito.   

Abstract

BACKGROUND: To obtain a clear understanding of the pathogenesis of lipoprotein glomerulopathy (LPG), we studied the role of the deficiency of Fc receptor gamma chain (FcRγ) for the development of LPG in concert with apolipoprotein E (apoE) abnormalities.
METHODS: We generated apoE and FcRγ double-knockout (FcRγ/apoE-KO) mice, and subsequently introduced several kinds of human recombinant apoE genes. At 21 days after infection, the mice were sacrificed and histologically examined. Peritoneal macrophages were evaluated for their response to modified lipids.
RESULTS: In the FcRγ/apoE-KO mice, the human apoE3-injected mice showed the most drastic LPG-like changes, as well as prominent hypertriglyceridemia. Meanwhile, relative to the human apoE3-injected mice, the FcRγ/apoE-KO mice showed greater lipoprotein deposition and less macrophage infiltration into the mesangial area. Moreover, the peritoneal macrophages in the apoE/FcRγ-KO mice were impaired in lipid uptake and secretion of the cytokines monocyte chemotactic protein-1 and regulated upon activation, normal T-cell expressed and secreted, after the uptake of oxidized low-density lipoprotein.
CONCLUSIONS: These results suggest that the impairment of macrophage function resulting from FcRγ deficiency plays a principal role in the development of LPG in the presence of apoE abnormalities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863838     DOI: 10.1093/ndt/gfs329

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

1.  Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.

Authors:  Ryosuke Usui; Masaki Takahashi; Kosaku Nitta; Minako Koike
Journal:  CEN Case Rep       Date:  2016-03-04

2.  A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I.

Authors:  Satoshi Takasaki; Akira Matsunaga; Kensuke Joh; Takao Saito
Journal:  CEN Case Rep       Date:  2018-01-22

Review 3.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 4.  Topics in lipoprotein glomerulopathy: an overview.

Authors:  Takao Saito; Akira Matsunaga; Kenji Ito; Hitoshi Nakashima
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

Review 5.  Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.

Authors:  Eduardo Cambruzzi; Karla Lais Pêgas
Journal:  J Bras Nefrol       Date:  2018-11-08

6.  Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.

Authors:  Mingxin Yang; Qinjie Weng; Xiaoxia Pan; Hafiz Muhammad Jafar Hussain; Shuwen Yu; Jing Xu; Xialian Yu; Yunzi Liu; Yuanmeng Jin; Chunli Zhang; Xiao Li; Hong Ren; Nan Chen; Jingyuan Xie
Journal:  Mol Genet Genomic Med       Date:  2020-05-22       Impact factor: 2.183

7.  Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.

Authors:  Hongyan Wu; Jing Yang; Yun-Qiang Liu; Song Lei; Mei Yang; Zhi Yang; Yuan Yang; Zhangxue Hu
Journal:  J Transl Med       Date:  2021-03-04       Impact factor: 5.531

8.  Macrophage Infiltration into the Glomeruli in Lipoprotein Glomerulopathy.

Authors:  Satoshi Takasaki; Kunihiko Maeda; Kensuke Joh; Shu Yamakage; Sachiko Fukase; Toshiyuki Takahashi; Masayuki Suzuki; Akira Matsunaga; Takao Saito
Journal:  Case Rep Nephrol Dial       Date:  2015-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.